Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.46 |
| ▸ | VSIR | Q9H7M9 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9777407 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM1AMAOAMAOBSLC40A1 | |
| SCHEMBL7653614 | 0.87 | CXCR4 (0.47) | SMN1; SMN2CD274PDCD1VSIRPDCD1LG2 | |
| SCHEMBL943003 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM1AMAOAMAOBNPSR1 | |
| SCHEMBL22564633 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM1AMAOAMAOBSLC40A1 | |
| SCHEMBL9777453 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM1AMAOAMAOBSLC40A1 | |
| SCHEMBL10483914 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2CD274PDCD1KDM1AMAOA | |
| SCHEMBL19603134 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM1AMAOAMAOBSLC40A1 | |
| SCHEMBL1038536 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2CD274KDM1AMAOAMAOB | |
| SCHEMBL10483884 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM1AMAOAMAOB | |
| SCHEMBL21986550 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101460453-B | Novel sulfonamide compounds | ACTELION PHARMACEUTICALS LTD | 2012-10-03 | — | — | CN | disclosed |
| US-8003654-B2 | N-glycinsulfonamide derivatives and uses as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-05 | — | — | US | disclosed |
| CN-101460453-A | Novel sulfonamide compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2007717-A1 | NOVEL SULFONAMIDE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116374-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | HCRTR2, HCRTR1, NPSR1 | SMN1; SMN2 1760/4885CD274 3412/4885PDCD1 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.